Product Description
| Product name |
Dapagliflozin |
| CAS |
461432-26-8 |
| Test Method |
HPLC |
| Purity |
99.3% |
| Appearance |
White Powder |
| Shelf life |
2 years |
| Storage |
Cool and dry place |
Dapagliflozin is developed by Bristol-Myers Squibb and AstraZeneca. It was approved by the EMA on November 12, 2012 and is the first to be approved. SGLT2 inhibitors for the type 2 diabetes are important candidates. They are used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Certificate of Analysis
Application
Dapagliflozin can be used for the type 2 diabetes.
Dapaglifloxin belongs to the inhibitor of sodium-glucose coordinated transport protein 2 (SGLT2), which can reduce the reabsorption of glucose by the kidney, promote the excretion of glucose from urine, and play a role in reducing glucose.
Dapaglifloxin has certain effects on weight reduction, blood pressure reduction and cardiovascular protection.
Recommended Products
| Hot-selling API products |
| SAME |
UMP |
Fullerenols |
Diphenhydramine |
| |
Minoxidil |
RU58841 |
Finasteride |
OEM service
Company Profile
Company Exhibition Information
FAQ
1. Customs clearance
1) By Express:
Normally there is no specical need for the recipient to clear the customs. If the customs has an objection,our rich experienced and peofessional group will help you clear the customs.
2) By Air and by Sea:
Our company will cooperate with the recipient to provide relevant file and information in the customs clearance procedure.
2.Payment
T/T,Western Union,MoneyGram,Trade Assurance Order,L/C etc.
Audited Supplier 
){kind=link}
){kind=link}